Transition Therapeutics Announces Executive Management Appointments



    TORONTO, July 3 /CNW/ - Transition Therapeutics Inc. ("Transition" or the
"Company") (TSX: TTH; NASDAQ:   TTHI) Chairman and Chief Executive Officer, 
Dr. Tony Cruz, is pleased to announce that Mr. Elie Farah has been appointed
President in addition to continuing to serve as Chief Financial Officer, and
Ms. Nicole Rusaw-George has been appointed to the position of Vice-President,
Finance.
    "These promotions reflect the strength of our management team and 
Mr. Farah's and Ms. Rusaw-George's expanding responsibilities in the growth of
the Company," commented Dr. Cruz.
    Since joining Transition in 2005 as Chief Financial Officer and
Vice-President, Corporate Development, Mr. Farah has demonstrated leadership
in the execution of the Company's strategic plan across all aspects of the
business. Also joining Transition in 2005, Ms. Rusaw-George has held the
position of Director of Finance with a focus in the areas of financial
reporting and regulatory compliance.

    About Transition
    ----------------
    Transition is a biopharmaceutical company, developing novel therapeutics
for disease indications with large markets. Transition's lead products include
ELND005 (AZD-103) for the treatment of Alzheimer's disease and TT-223 for the
treatment of diabetes. Transition has an emerging pipeline of preclinical drug
candidates acquired externally or developed internally using its proprietary
drug discovery engine. Transition's shares are listed on the NASDAQ under the
symbol "TTHI" and the Toronto Stock Exchange under the symbol "TTH". For
additional information about the Company, please visit
www.transitiontherapeutics.com.

    Notice to Readers: Information contained in our press releases should be
considered accurate only as of the date of the release and may be superseded
by more recent information we have disclosed in later press releases, filings
with the OSC, SEC or otherwise. Except for historical information, this press
release may contain forward-looking statements, relating to expectations,
plans or prospects for Transition, including conducting clinical trials. These
statements are based upon the current expectations and beliefs of Transition's
management and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include factors
beyond Transition's control and the risk factors and other cautionary
statements discussed in Transition's quarterly and annual filings with the
Canadian commissions.

    %SEDAR: 00015806E




For further information:

For further information: on Transition, visit
www.transitiontherapeutics.com or contact: Dr. Tony Cruz, Chief Executive
Officer, Transition Therapeutics Inc, Phone: (416) 260-7770, x.223,
tcruz@transitiontherapeutics.com; Elie Farah, President & Chief Financial
Officer, Transition Therapeutics Inc., Phone: (416) 260-7770, x.203,
efarah@transitiontherapeutics.com

Organization Profile

Transition Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890